{"id":"W4387903322","doi":"10.1038/s41467-023-42400-5","title":"Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial","year":2023,"lang":"en","type":"article","venue":"Nature Communications","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Universität Heidelberg; Bristol-Myers Squibb Canada; Deutsches Krebsforschungszentrum","keywords":"Ipilimumab; Nivolumab; Refractory (planetary science); Medicine; Oncology; Primary (astronomy); Cancer; Internal medicine; Clinical trial; Immunotherapy; Biology; Physics","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001867362,0.0009740953,0.001622311,0.0001802824,0.0003391558,0.001108982,0.0006003567,0.001302497,0.003985235],"category_scores_gemma":[0.0009595106,0.00031105,0.001382289,0.0002660826,0.0005838525,0.0005674801,0.0003109406,0.002696229,0.0008722379],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007240126,"about_ca_system_score_gemma":0.00110604,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005598566,"about_ca_topic_score_gemma":0.001337781,"domain_scores_codex":[0.9995234,0.0002794475,0.00002256114,0.00007221864,0.00003379175,0.00006857271],"domain_scores_gemma":[0.9994357,0.0001231348,0.00008631479,0.00004452331,0.00004291698,0.0002674373],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8692873,0.02523641,0.003018596,0.001748854,0.002240219,0.0002030446,0.0001770525,0.001261979,0.01221432,0.0004119214,0.007368193,0.07683215],"study_design_scores_gemma":[0.8980806,0.0934294,0.003087196,0.00009981416,0.000534104,0.0001181274,0.00003616109,0.000831236,0.0008461652,0.0002512874,0.002667838,0.00001807081],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9762864,0.01129183,0.0007975237,0.001501462,0.0005738719,0.003881613,0.00176267,0.0001263388,0.003778324],"genre_scores_gemma":[0.9816144,0.004327454,0.001652123,0.001952465,0.0004153834,0.004379935,0.001901614,0.000030037,0.003726488],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003985235,"threshold_uncertainty_score":0.01333189,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06261548164402625,"score_gpt":0.4218822484764692,"score_spread":0.359266766832443,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}